HAV Vaccine

Phase 3Vaccine

Takeda

HAV Vaccine is one of 3 biologic programs targeting HPV Vaccination. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HPV VaccinationNot yet recruiting

HPV VaccinationPhase 3

Not yet recruiting

Competition

Competitive Landscape

3 competitors in HPV Vaccination

#DrugCompanyPhaseTrials

HPV Vaccine

SShanghai Zerun Biotechnology Co.,Ltd

Phase 3

2 2

Bivalent HPV Vaccine

ZZagazig University

Phase 3

1 3

HAV Vaccine

Takeda

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Not yet recruiting

HPV Vaccination

NCT05173324

Clinical

Trials by Indication[1]

HPV Vaccination1 trial

Integration of HPV Vaccination and HPV-based Cervical Screening Into ARV Clinics: the H2VICTORY Trial

Not yet recruiting·IInternational Agency for Research on Cancer·Phase 3·NCT05173324·8,000 enrolled

Hepatitis1 trial

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine

Completed· Takeda logo

Takeda·Phase 3·NCT03525119·900 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for HAV Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HAV Vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HAV Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 3[1]
Company: Takeda

HAV Vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

HPV Vaccination1 trial

Hepatitis1 trial

References

Drug Info

Quick Facts

Related News